Identifying and addressing the toxicity of checkpoint inhibitors in lung cancer

Clin Adv Hematol Oncol. 2016 Mar;14(3):165-7.

Author

Julie R Brahmer¹

Affiliation

¹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, Maryland.

PMID: 27058029

No abstract available

Publication types

Interview

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Autoimmune Diseases / diagnosis
Autoimmune Diseases / etiology
B7-H1 Antigen / antagonists & inhibitors
CTLA-4 Antigen / antagonists & inhibitors
Humans
Immunotherapy / adverse effects
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / metabolism
Molecular Targeted Therapy / adverse effects*
Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

Antineoplastic Agents
B7-H1 Antigen
CTLA-4 Antigen
Programmed Cell Death 1 Receptor